Please login to the form below
FDA awards grant for cancer drug study
The US FDA has awarded a $1.6m grant under its orphan drugs programme to a Alabama-based biotech company Egen to help the company with clinical trials of a potential new therapy for ovarian cancer
The US Food and Drug Administration (FDA) has awarded a $1.6m grant under its orphan drugs programme to a small, Alabama-based biotech company called Egen to help the company with clinical trials of a potential new therapy for ovarian cancer.
The four-year grant is intended to assist in the phase II clinical development of the privately held company's lead product, Egen-001, which is being developed for the treatment of advanced recurrent ovarian cancer.
The drug is an interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 enhances the body's immune system against cancer and inhibits tumour blood supply, according to Egen.
The product has completed two phase I trials: one as monotherapy in platinum-resistant ovarian cancer patients, and the other in combination with carboplatin/docetaxel chemotherapy in platinum-sensitive ovarian cancer patients.
The FDA granted orphan drug status to Egen-001 in 2005. The status, which is reserved for drugs intended to treat diseases that affect fewer than 200,000 Americans, carries a number of benefits, including seven years of US marketing exclusivity, tax breaks and eligibility for help with clinical trial costs.
This is Egen's second grant for the drug from the FDA. The first, totaling $1m, was awarded in 2005.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- STEM Healthcare founder Rob Wood secures a 25% stake in performance-io
- Sinopharm’s COVID-19 vaccine scores approval in China
- Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- Roche, Genentech partner with The Weill Neurohub on ten-year neuroscience collaboration
- EMA begins rolling review process for Sputnik V COVID-19 vaccine
- MHRA to fast-track vaccines modified for new COVID-19 variants
- Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC
- Syneos Health Communications announces senior hires to Europe-based team
- Live Webinar: Search Listening as a Tool to Inform Brand Strategy & Enable Patient-Centricity
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
- A cultural shift in clinical research
- Research organisations across the board are experimenting with new technologies...
Quick links
Infographics
